Source comparison
Melanotan-1 Dosing Protocol Comparison
Loading Phase 0.25–1mg Daily 10–14 days 5–10 min within 1 hour post-injection Visible pigmentation increase; receptor saturation Maintenance Phase 0.25–0.5mg 2–3x weekly Ongoing (12–16 weeks typical) 5 min within 1 hour post-injection Sustained pigmentation; m
This comparison does not assign a generated winner or score.
- Loading Phase
- 0.25–1mg
- Daily
- 10–14 days
- 5–10 min within 1 hour post-injection
- Visible pigmentation increase; receptor saturation
- Maintenance Phase
- 0.25–0.5mg
- 2–3x weekly
- Ongoing (12–16 weeks typical)
- 5 min within 1 hour post-injection
- Sustained pigmentation; minimal additional darkening
- Tolerance Test
- 0.25mg
- Once
- Day 1–3
- Optional (monitor for nausea before UV)
- Assess GI tolerance before dose escalation
- High-Response Protocol
- 0.5–0.75mg
- 10 days
- 8–10 min UVB at 0.75 MED
- Rapid pigmentation for Type I–II skin; higher nausea risk
- Minimal Protocol
- 3x weekly
- 14–21 days
- 5 min post-injection
- Gradual pigmentation; lowest side effect profile
- Professional Assessment
- Start low (0.25mg), titrate based on nausea tolerance and pigmentation response. UV exposure is non-negotiable. Without it, melanocyte activation doesn't occur.